| scholarly article | Q13442814 |
| P50 | author | Ana M Moreno | Q87888724 |
| P2093 | author name string | Prashant Mali | |
| Atharv Worlikar | |||
| Dhruva Katrekar | |||
| Genghao Chen | |||
| P2860 | cites work | 1.3-Dipolare Cycloadditionen, XXXII. Kinetik der Additionen organischer Azide an CC-Mehrfachbindungen | Q56486250 |
| Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients | Q83720294 | ||
| Folding DNA to create nanoscale shapes and patterns | Q22122462 | ||
| Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism | Q24515072 | ||
| The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. | Q24533492 | ||
| Self-assembly of DNA into nanoscale three-dimensional shapes | Q24653833 | ||
| Genetic code expansion in stable cell lines enables encoded chromatin modification | Q27313603 | ||
| Structure of AAV-DJ, a Retargeted Gene Therapy Vector: Cryo-Electron Microscopy at 4.5 Å Resolution | Q27681347 | ||
| ADENOVIRUS-ASSOCIATED DEFECTIVE VIRUS PARTICLES | Q28202390 | ||
| Expanding the genetic code of Escherichia coli | Q28213675 | ||
| A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes | Q28219495 | ||
| A strain-promoted [3 + 2] azide-alkyne cycloaddition for covalent modification of biomolecules in living systems | Q28293869 | ||
| Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro | Q28476756 | ||
| Novel MUC1 aptamer selectively delivers cytotoxic agent to cancer cells in vitro | Q28481099 | ||
| Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response | Q29619095 | ||
| Directed evolution of adeno-associated virus yields enhanced gene delivery vectors | Q33232270 | ||
| In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses | Q33327474 | ||
| Naturally enveloped AAV vectors for shielding neutralizing antibodies and robust gene delivery in vivo | Q33924645 | ||
| AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. | Q34168942 | ||
| Genome editing assessment using CRISPR Genome Analyzer (CRISPR-GA). | Q34285352 | ||
| Development of an intein-mediated split-Cas9 system for gene therapy | Q34481059 | ||
| Synthetic virology: engineering viruses for gene delivery | Q34487264 | ||
| Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector | Q34633598 | ||
| Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? | Q34634722 | ||
| Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection | Q34770058 | ||
| Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors | Q34938807 | ||
| Adeno-associated virus capsids displaying immunoglobulin-binding domains permit antibody-mediated vector retargeting to specific cell surface receptors | Q34998573 | ||
| Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models | Q35665240 | ||
| Adenovirus-associated virus vector-mediated gene transfer in hemophilia B | Q35691659 | ||
| Broadening the versatility of lentiviral vectors as a tool in nucleic acid research via genetic code expansion | Q35770576 | ||
| In Silico Reconstruction of the Viral Evolutionary Lineage Yields a Potent Gene Therapy Vector | Q35952312 | ||
| Production and characterization of adeno-associated viral vectors | Q36779416 | ||
| Efficient viral delivery system for unnatural amino acid mutagenesis in mammalian cells. | Q37031825 | ||
| DNA aptamer-mediated cell targeting | Q37222769 | ||
| Viral capsid DNA aptamer conjugates as multivalent cell-targeting vehicles | Q37331276 | ||
| Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain | Q37382030 | ||
| A multifunctional AAV-CRISPR-Cas9 and its host response | Q37731772 | ||
| Engineering adeno-associated viruses for clinical gene therapy | Q38212776 | ||
| Nucleotide sequence and organization of the adeno-associated virus 2 genome | Q40143539 | ||
| Barcoding cells using cell-surface programmable DNA-binding domains | Q40282743 | ||
| PEG conjugation moderately protects adeno-associated viral vectors against antibody neutralization | Q40413171 | ||
| A Precise Chemical Strategy To Alter the Receptor Specificity of the Adeno-Associated Virus. | Q40639680 | ||
| Expansion of the genetic code: site-directed p-fluoro-phenylalanine incorporation in Escherichia coli | Q41819313 | ||
| Efficient multisite unnatural amino acid incorporation in mammalian cells via optimized pyrrolysyl tRNA synthetase/tRNA expression and engineered eRF1 | Q41831028 | ||
| Folding DNA into twisted and curved nanoscale shapes | Q41851751 | ||
| Glycated AAV vectors: chemical redirection of viral tissue tropism | Q42093895 | ||
| Displaying high-affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transfer | Q42541148 | ||
| Three-dimensional structures self-assembled from DNA bricks | Q42860917 | ||
| Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients | Q43466855 | ||
| Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors | Q43740107 | ||
| Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors | Q44258968 | ||
| Combinatorial engineering of a gene therapy vector: directed evolution of adeno-associated virus | Q45422552 | ||
| Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). | Q45747007 | ||
| Quantitative analysis of the packaging capacity of recombinant adeno-associated virus | Q45766162 | ||
| Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. | Q45882349 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3589 | |
| P577 | publication date | 2018-02-26 | |
| P1433 | published in | Scientific Reports | Q2261792 |
| P1476 | title | Oligonucleotide conjugated multi-functional adeno-associated viruses | |
| P478 | volume | 8 |
| Q64040883 | Adeno-associated virus vector as a platform for gene therapy delivery |
| Q100737258 | Base editing: advances and therapeutic opportunities |
| Q91936196 | Engineering the AAV capsid to evade immune responses |
| Q91559185 | Functional maturation of human neural stem cells in a 3D bioengineered brain model enriched with fetal brain-derived matrix |
| Q91062934 | Liposomal delivery of CRISPR/Cas9 |
| Q94474209 | Positron emission tomography imaging of novel AAV capsids maps rapid brain accumulation |
| Q91259654 | Safety and efficacy evaluations of an adeno-associated virus variant for preparing IL10-secreting human neural stem cell-based therapeutics |
| Q59354985 | Synthesis at the interface of virology and genetic code expansion |
| Q92050917 | Using genetically incorporated unnatural amino acids to control protein functions in mammalian cells |
Search more.